Zalviso (sufentanil)
- Region
- 🇪🇺 EU
- Active substance
- sufentanil
- Company
- FGK Representative Service GmbH
- Status
- Withdrawn
- Therapeutic area
- Pain, Postoperative
- CHMP opinion
- Thu 23 Jul 2015
- EU approval
- Fri 18 Sep 2015
- Application
- EMEA/H/C/002784
- ATC
- N01AH03
- Official record
- www.ema.europa.eu
Indication
Zalviso is indicated for the management of acute moderate to severe post-operative pain in adult patients.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
Follow Zalviso
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.